Antiviral activity of ethanol extract of Lophatherum gracile against respiratory syncytial virus infection

被引:26
|
作者
Chen, Li-Feng [1 ]
Zhong, Yuan-Lin [1 ]
Luo, Ding [1 ]
Liu, Zhong [2 ]
Tang, Wei [1 ]
Cheng, Wen [1 ]
Xiong, Si [1 ]
Li, Yao-Lan [1 ]
Li, Man-Mei [1 ]
机构
[1] Jinan Univ, Coll Pharm, Inst Tradit Chinese Med & Nat Prod, Guangzhou 510632, Guangdong, Peoples R China
[2] Jinan Univ, Coll Life Sci & Technol, Guangzhou Jinan Biomed Res & Dev Ctr, Guangdong Prov Key Lab Bioengn Med, Guangzhou, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Lophatherum gracile; Respiratory syncytial virus; Inflammation; Antiviral; Traditional Chinese medicine; IN-VITRO; T-CELLS; PATHOGENESIS; ISOORIENTIN; FLAVONOIDS; PREVENTION; RECEPTORS; LEAVES; HELPER;
D O I
10.1016/j.jep.2018.10.036
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharinacological relevance: Lophatherum gracile, an important medicinal plant, is used traditionally in the treatment of cough associated with lung heat and inflammation. In this study, an ethanol extract of L. gracile (DZY) was shown to inhibit respiratory syncytial virus (RSV) infection and RSV-induced inflammation in vitro and in vivo. These findings provide a strong and powerful support for the traditional use of L. gracile in the treatment of RSV-related diseases. Aim of the study: To determine the anti-RSV activities of DZY and its ingredients, and explore the relationship between RSV infection and inflammation. Materials and methods: DZY was extracted from L. gracile and its major ingredients were determined by high-performance liquid chromatography (HPLC). RSV-infected HEp-2 and RAW264.7 cell models were established to assess the inhibitory effect of DZY on RSV replication and nitric oxide (NO) production in vitro. Three-week-old BALB/c mice challenged intranasally with RSV were used to establish RSV-infected animal mode. The mice were respectively administered DZY at high-, middle-, and low-dose in different groups. The anti-RSV activity of DZY was evaluated by detecting viral load, lung lesion, CD4(+) and CD8(+) T cell population, and interleukin (IL)-1 beta, tumor necrosis factor (TNF)-alpha, and interferon (IFN)-gamma expression in the lung tissue. Results: In HEp-2 cell line, DZY effectively inhibited RSV infection in a dose-dependent manner with IC50 values of 20 mu g/mL against RSV (Long strain) and IC50 values of 25 mu g/mL against RSV (A2 strain). The anti-RSV activity of DZY was mainly determined by isoorientin, swertiajaponin, 3, 5-di-caffeoylquinic acid, and 3, 4-di-caffeoylquinic acid. Moreover, DZY suppressed NO production induced by RSV in vitro. In vivo, oral administration of DZY significantly reduced the viral load and ameliorated lesions in the lung tissue. A probable antiviral mechanism was mediated by slightly improving the ratio of CD4(+)/CD8(+) T cells and inhibiting the mRNA and protein expression of IL-1 beta, TNF-alpha, and IFN-gamma. Conclusions: (1) DZY exhibits anti-RSV activities both in vitro and in vivo. (2) RSV infection can trigger a series of inflammatory reactions; thus, ameliorating inflammation is helpful to control the course of disease caused by RSV. These findings provide the rationale and scientific evidence behind the extensive use of L. gracile in traditional medicine for the treatment of diseases potentially caused by RSV.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo
    L. Shi
    H. Xiong
    J. He
    H. Deng
    Q. Li
    Q. Zhong
    W. Hou
    L. Cheng
    H. Xiao
    Z. Yang
    Archives of Virology, 2007, 152 : 1447 - 1455
  • [22] Antiviral Effect of Cimicifugin from Cimicifuga foetida Against Human Respiratory Syncytial Virus
    Wang, Kuo-Chih
    Chang, Jung-San
    Lin, Liang-Tzung
    Chiang, Lien-Chai
    Lin, Chun-Ching
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2012, 40 (05): : 1033 - 1045
  • [23] Development of an inhalable antiviral powder formulation against respiratory syncytial virus
    Heida, Rick
    Akkerman, Renate
    Silva, Paulo H. Jacob
    Lakerveld, Anke J.
    Ortiz, Daniel
    Bigogno, Chiara
    Gasbarri, Matteo
    Kasteren, Puck B. van
    Stellacci, Francesco
    Frijlink, Henderik W.
    Huckriede, Anke L. W.
    Hinrichs, Wouter L. J.
    JOURNAL OF CONTROLLED RELEASE, 2023, 357 : 264 - 273
  • [24] Lactobacillus mucosae exerted different antiviral effects on respiratory syncytial virus infection in mice
    Wang, Qianwen
    Fang, Zhifeng
    Li, Lingzhi
    Wang, Hongchao
    Zhu, Jinlin
    Zhang, Pinghu
    Lee, Yuan-kun
    Zhao, Jianxin
    Zhang, Hao
    Lu, Wenwei
    Chen, Wei
    FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [25] Respiratory Syncytial Virus Infection: An Update
    Soni, Akshita
    Kabra, S. K.
    Lodha, Rakesh
    INDIAN JOURNAL OF PEDIATRICS, 2023, 90 (12) : 1245 - 1253
  • [26] Nasally administered Lactobacillus rhamnosus strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infection
    Tomosada, Yohsuke
    Chiba, Eriko
    Zelaya, Hortensia
    Takahashi, Takuya
    Tsukida, Kohichiro
    Kitazawa, Haruki
    Alvarez, Susana
    Villena, Julio
    BMC IMMUNOLOGY, 2013, 14
  • [27] Synthesis of three triterpene series and their activity against respiratory syncytial virus
    Santos da Silva, Gloria N.
    Atik, Diana Monti
    Antunes Fernandes, Jheini L.
    do Nascimento, Deise de Freitas
    Fazolo, Tiago
    Duarte de Souza, Ana Paula
    Baggio Gnoatto, Simone C.
    ARCHIV DER PHARMAZIE, 2018, 351 (08)
  • [28] Linear and dendrimeric antiviral peptides: design, chemical synthesis and activity against human respiratory syncytial virus
    Kozhikhova, Ksenia V.
    Shilovskiy, Igor P.
    Shatilov, Artem A.
    Timofeeva, Anastasiia V.
    Turetskiy, Evgeny A.
    Vishniakova, Liudmila, I
    Nikolskii, Aleksandr A.
    Barvinskaya, Ekaterina D.
    Karthikeyan, Subramani
    Smirnov, Valeriy V.
    Kudlay, Dmitriy A.
    Andreev, Sergey M.
    Khaitov, Musa R.
    JOURNAL OF MATERIALS CHEMISTRY B, 2020, 8 (13) : 2607 - 2617
  • [29] Immunobiotic Lactobacillus rhamnosus improves resistance of infant mice against respiratory syncytial virus infection
    Chiba, Eriko
    Tomosada, Yohsuke
    Guadalupe Vizoso-Pinto, Maria
    Salva, Susana
    Takahashi, Takuya
    Tsukida, Kohichiro
    Kitazawa, Haruki
    Alvarez, Susana
    Villena, Julio
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2013, 17 (02) : 373 - 382
  • [30] Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis
    Robinson, Karen A.
    Odelola, Olaide A.
    Saldanha, Ian J.
    Mckoy, Naomi A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (02):